Thymic Carcinoma

News alerts, weekly reports and conference planners

Related cancers:

‹

Thymus Cancer (55)

Thymoma (21)

Thymus Cancer (55)

Thymoma (21)

›

No biomarker	Thymic Carcinoma	No biomarker	Thymic Carcinoma	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1
No biomarker	Thymic Carcinoma	No biomarker	Thymic Carcinoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Thymic Carcinoma	No biomarker	Thymic Carcinoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Thymic Carcinoma	No biomarker	Thymic Carcinoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
KIT mutation	Thymic Carcinoma	KIT mutation	Thymic Carcinoma	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2
No biomarker	Thymic Carcinoma	No biomarker	Thymic Carcinoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Thymic Carcinoma	No biomarker	Thymic Carcinoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Thymic Carcinoma	No biomarker	Thymic Carcinoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Thymic Carcinoma	No biomarker	Thymic Carcinoma	prednisone Sensitive: A2 - Guideline prednisone Sensitive : A2	prednisone Sensitive: A2 - Guideline prednisone Sensitive : A2
No biomarker	Thymic Carcinoma	No biomarker	Thymic Carcinoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Thymic Carcinoma	No biomarker	Thymic Carcinoma	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2
No biomarker	Thymic Carcinoma	No biomarker	Thymic Carcinoma	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2
No biomarker	Thymic Carcinoma	No biomarker	Thymic Carcinoma	ifosfamide Sensitive: A2 - Guideline ifosfamide Sensitive : A2	ifosfamide Sensitive: A2 - Guideline ifosfamide Sensitive : A2
No biomarker	Thymic Carcinoma	No biomarker	Thymic Carcinoma	etoposide oral Sensitive: A2 - Guideline etoposide oral Sensitive : A2	etoposide oral Sensitive: A2 - Guideline etoposide oral Sensitive : A2
No biomarker	Thymic Carcinoma	No biomarker	Thymic Carcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Thymic Carcinoma	No biomarker	Thymic Carcinoma	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
No biomarker	Thymic Carcinoma	No biomarker	Thymic Carcinoma	prednisone + octreotide Sensitive: A2 - Guideline prednisone + octreotide Sensitive : A2	prednisone + octreotide Sensitive: A2 - Guideline prednisone + octreotide Sensitive : A2
No biomarker	Thymic Carcinoma	No biomarker	Thymic Carcinoma	octreotide Sensitive: A2 - Guideline octreotide Sensitive : A2	octreotide Sensitive: A2 - Guideline octreotide Sensitive : A2
No biomarker	Thymic Carcinoma	No biomarker	Thymic Carcinoma	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2	everolimus Sensitive: A2 - Guideline everolimus Sensitive : A2
No biomarker	Thymic Carcinoma	No biomarker	Thymic Carcinoma	pemetrexed Sensitive: A2 - Guideline pemetrexed Sensitive : A2	pemetrexed Sensitive: A2 - Guideline pemetrexed Sensitive : A2
No biomarker	Thymic Carcinoma	No biomarker	Thymic Carcinoma	gemcitabine + capecitabine Sensitive: A2 - Guideline gemcitabine + capecitabine Sensitive : A2	gemcitabine + capecitabine Sensitive: A2 - Guideline gemcitabine + capecitabine Sensitive : A2
No biomarker	Thymic Carcinoma	No biomarker	Thymic Carcinoma	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2	sunitinib Sensitive: A2 - Guideline sunitinib Sensitive : A2
EIF4EBP1 expression	Thymic Carcinoma	EIF4EBP1 expression	Thymic Carcinoma	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3
HER-2 positive	Thymic Carcinoma	HER-2 positive	Thymic Carcinoma	pyrotinib Sensitive: C3 – Early Trials pyrotinib Sensitive : C3	pyrotinib Sensitive: C3 – Early Trials pyrotinib Sensitive : C3
HER-2 mutation	Thymic Carcinoma	HER-2 mutation	Thymic Carcinoma	pyrotinib Sensitive: C3 – Early Trials pyrotinib Sensitive : C3	pyrotinib Sensitive: C3 – Early Trials pyrotinib Sensitive : C3
IGF1R expression	Thymic Carcinoma	IGF1R expression	Thymic Carcinoma	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3
KIT exon 17 mutation	Thymic Carcinoma	KIT exon 17 mutation	Thymic Carcinoma	avapritinib Sensitive: C3 – Early Trials avapritinib Sensitive : C3	avapritinib Sensitive: C3 – Early Trials avapritinib Sensitive : C3
SP140 overexpression	Thymic Carcinoma	SP140 overexpression	Thymic Carcinoma	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
PD-L1 expression	Thymic Carcinoma	PD-L1 expression	Thymic Carcinoma	KN046 Sensitive: C3 – Early Trials KN046 Sensitive : C3	KN046 Sensitive: C3 – Early Trials KN046 Sensitive : C3
KIT D820Y	Thymic Carcinoma	KIT D820Y	Thymic Carcinoma	sorafenib Sensitive: C4 – Case Studies sorafenib Sensitive : C4	sorafenib Sensitive: C4 – Case Studies sorafenib Sensitive : C4
PD-L1 overexpression	Thymic Carcinoma	PD-L1 overexpression	Thymic Carcinoma	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4
EGFR exon 20 insertion	Thymic Carcinoma	EGFR exon 20 insertion	Thymic Carcinoma	anlotinib Sensitive: C4 – Case Studies anlotinib Sensitive : C4	anlotinib Sensitive: C4 – Case Studies anlotinib Sensitive : C4

Thymic Carcinoma

Associations(34)

Associations
(34)